These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6974167)

  • 1. The semi-synthetic thienamycin derivative MK0787 and its properties with respect to a range of beta-lactamases from clinically relevant bacterial species.
    RIchmond MH
    J Antimicrob Chemother; 1981 Mar; 7(3):279-85. PubMed ID: 6974167
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains.
    Toda M; Sato K; Nakazawa H; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Nov; 18(5):837-8. PubMed ID: 6969580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-Formimidoyl thienamycin (MK0787): in-vitro antibacterial activity and susceptibility to beta-lactamases compared with that of cefotaxime, moxalactam and other beta-lactam antibiotics.
    Hanslo D; King A; Shannon K; Warren C; Phillips I
    J Antimicrob Chemother; 1981 Jun; 7(6):607-17. PubMed ID: 6265426
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of inhibitors of beta-lactamases on beta-lactamase extracts and on intact cells.
    Li JT; Moosdeen F; Williams JD
    J Antimicrob Chemother; 1982 Apr; 9(4):287-96. PubMed ID: 6282800
    [No Abstract]   [Full Text] [Related]  

  • 5. N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.
    Wise R; Andrews JM; Patel N
    J Antimicrob Chemother; 1981 May; 7(5):521-9. PubMed ID: 6790507
    [No Abstract]   [Full Text] [Related]  

  • 6. In-vitro activity of MK0787 (N-formimidoyl thienamycin) against Pseudomonas aeruginosa and other Gram-negative organisms and its stability to their beta-lactamases.
    Livermore DM; Williams RJ; Williams JD
    J Antimicrob Chemother; 1981 Nov; 8(5):355-62. PubMed ID: 6798011
    [No Abstract]   [Full Text] [Related]  

  • 7. Sch 29482: stability and inhibitory potency towards beta-lactamases from Gram-negative bacteria.
    Pechère JC; Letarte R; Guay R; Asselin C; Morin C
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():123-32. PubMed ID: 6977528
    [No Abstract]   [Full Text] [Related]  

  • 8. Beta-lactamases with high activity against imipenem and Sch 34343 from Aeromonas hydrophila.
    Shannon K; King A; Phillips I
    J Antimicrob Chemother; 1986 Jan; 17(1):45-50. PubMed ID: 3485091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative inhibition beta-lactamases by novel beta-lactam compounds.
    Fu KP; Neu HC
    Antimicrob Agents Chemother; 1979 Feb; 15(2):171-6. PubMed ID: 311616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-lactamase stability of faropenem.
    Dalhoff A; Nasu T; Okamoto K
    Chemotherapy; 2003 Sep; 49(5):229-36. PubMed ID: 14504433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibition.
    Barry AL; Jones RN; Wilson HW; Badal RE; Thornsberry C
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():97-112. PubMed ID: 6977536
    [No Abstract]   [Full Text] [Related]  

  • 12. Progress toward inhibitors of metallo-β-lactamases.
    McGeary RP; Tan DT; Schenk G
    Future Med Chem; 2017 May; 9(7):673-691. PubMed ID: 28504895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescein-labeled beta-lactamase mutant for high-throughput screening of bacterial beta-lactamases against beta-lactam antibiotics.
    Chan PH; Chan KC; Liu HB; Chung WH; Leung YC; Wong KY
    Anal Chem; 2005 Aug; 77(16):5268-76. PubMed ID: 16097768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Lactamases: Why and How.
    Pratt RF
    J Med Chem; 2016 Sep; 59(18):8207-20. PubMed ID: 27232275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antibacterial activity of thienamycin against multiresistant bacteria-comparison with beta-lactamase stable compounds.
    Romagnoli MF; Fu KP; Neu HC
    J Antimicrob Chemother; 1980 Sep; 6(5):601-6. PubMed ID: 6967870
    [No Abstract]   [Full Text] [Related]  

  • 16. R-factor mediated beta-lactamase production by Haemophilus influenzae.
    Sykes RB; Matthew M; O'Callaghan CH
    J Med Microbiol; 1975 Aug; 8(3):437-41. PubMed ID: 1080810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between carbenicillin and beta-lactamases from Gram-negative bacteria.
    Bobrowski M; Borowski E
    J Gen Microbiol; 1971 Nov; 68(3):263-72. PubMed ID: 5002807
    [No Abstract]   [Full Text] [Related]  

  • 18. β-Lactamases: A Focus on Current Challenges.
    Bonomo RA
    Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27742735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-lactamase inactivation by mechanism-based reagents.
    Fisher J; Belasco JG; Charnas RL; Khosla S; Knowles JR
    Philos Trans R Soc Lond B Biol Sci; 1980 May; 289(1036):309-19. PubMed ID: 6109326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of Sch 34343 against Gram-negative bacteria producing characterized beta-lactamases.
    Dornbusch K; Frolander F; Cacciapuoti AF; Naples L; Hare RS; Miller GH
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():85-97. PubMed ID: 3897175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.